Search
Jimmy’s battle with RSV reminds us that research can change young lives.
Geoff Cattach has headed the Children's Leukaemia & Cancer Research Foundation and raised $24 million to fund The Kids' research into childhood cancers
Research
Childhood pneumonia in the Eastern Highlands Province of Papua New Guinea: clinical, microbiological and immunological predictors of diseaseChristopher Deborah Hannah Lea-Ann Peter Blyth Lehmann Moore Kirkham Richmond MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc OAM BSc (Hons)
Research
Infection Transmission in Early Childhood Education and Care: a mixed methods study to inform future interventionsThe COVID-19 pandemic has exposed many uncertainties and incorrect assumptions about respiratory pathogen transmission.
Research
ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in childrenChris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health
Research
Australian Group on Antimicrobial Resistance surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns in Australian children and adolescents 2022 - 2023Between January 2022 and December 2023, there were 1,827 bloodstream infection (BSI) isolates in 1,745 children and adolescents reported to the Australian Group on Antimicrobial Resistance (AGAR) surveillance outcome programs, with 40% of episodes in children aged < 12 months.
Research
Predicting regional and temporal incidence of RSV and influenza hospitalizations in a birth cohort of young Australian childrenWestern Australia experiences multiple climatic zones, influencing the epidemiology of respiratory viruses. We aimed to estimate the true incidence of respiratory syncytial virus and influenza hospitalizations across these different climatic regions using predictive modelling.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Defining the cellular immune response to vaccines for enhanced protection from invasive pneumococcal diseasePeter Lea-Ann Ruth Richmond Kirkham Thornton MBBS MRCP(UK) FRACP PhD PhD Head, Vaccine Trials Group Co-Head, Bacterial Respiratory Infectious Disease
News & Events
Top-up funding announced to fast-track clinical trials of Spritz-OMResearchers developing a nasal therapy to prevent childhood ear infections and reduce overuse of antibiotics have received $300,000 in top-up funding.